Long-term follow-up of antibody titers after hepatitis A vaccination |
| |
| Affiliation: | 1. Third Department of Internal Medicine, Kumamoto University School of Medicine, Kumamoto, Japan;2. The Chemo-Sero-Therapeutic Research Institute, Kumamoto, Japan;1. Neuroscience Graduate Program, University of California, San Francisco, San Francisco, CA 94158, USA;2. Kavli Institute for Fundamental Neuroscience, and Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA 94158, USA;3. Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA;4. Department of Psychology, and Princeton Neuroscience Institute, Princeton University, Princeton, Princeton, NJ 08544, USA;5. Department of Physiology, University of California, San Francisco, San Francisco, CA 94158, USA;6. Department of Neurology and Department of Psychiatry and Behavioral Science, University of California, San Francisco, San Francisco, CA 94158, USA;1. Ministry of Agriculture Key Laboratory of Crop Nutrition and Fertilization, Institute of Agricultural Resources and Regional Planning, Chinese Academy of Agricultural Sciences, Beijing 100081, PR China;2. Department of Microbiology and Plant Biology, University of Oklahoma, 101 David L Boren Boulevard, Norman, OK 73019, USA;1. Centre of Public Health Sciences, Faculty of Medicine, University of Iceland, Reykjavik, Iceland;2. Life Science Team, Bech-Bruun Law Firm, Copenhagen, Denmark;3. Barcelona Clinic Schizophrenia Unit, Neuroscience Institute, and Hospital Clínic, Department of Medicine, Barcelona University, and Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain;4. Centre for Pharmacoepidemiology, Department of Medicine, Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden;5. Pharmacy Department of Barcelona Health Region, Catalan Health Service (CatSalut), Barcelona, Spain;6. Division of Mental and Physical Health, Norwegian Institute of Public Health, Norway;7. Medicines Reimbursement Department, National Health Insurance Fund of the Republic of Lithuania, Vilnius, Lithuania, and Faculty of Medicine, Department of Pathology, Forensic Medicine and Pharmacology, Vilnius University, Lithuania;8. Department of Health Services Research, Carl von Ossietzky University Oldenburg, Germany;9. Brigham and Women׳s Hospital, Harvard Medical School, Boston, MA, USA;10. University of Groningen, University Medical Center Groningen, Department of Psychiatry, The Netherlands;11. Department of Pharmacoepidemiology and Clinical Research Management, Graduate School of Medicine and Public Health, Kyoto University, Japan;12. Medicines Policy Research Unit, Centre for Big Data Research in Health, University of New South Wales, Sydney, Australia;13. Grupo de Investigación en Farmacoepidemiología y Farmacovigilancia, Universidad Tecnológica de Pereira – Audifarma S.A., Pereira, Colombia;14. New Zealand׳s National School of Pharmacy, University of Otago, Dunedin, New Zealand;15. Kela Research, The Social Insurance Institution, Helsinki, Finland;p. Unit of Pharmacotherapy, -Epidemiology and -Economics, Department of Pharmacy, University of Groningen, The Netherlands;q. Community Medicine Research Center, Chang Gung Memorial Hospital, Keelung, Taiwan, and Institute of Molecular Biology, Academia Sinica, Taipei, and Department of Nutrition, Chang Gung University of Science and Technology, Kwei-Shan, Taiwan;r. University of Bordeaux, INSERM, Bordeaux Population Health Research Center, Team Pharmaco-epidemiology, UMR 1219, F33000 Bordeaux, France;s. Department of Child & Adolescent Psychiatry, Kaohsiung Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Kaohsiung, Taiwan;t. Freelance Researcher, Marburg, Germany;1. Neuroscience Institute, New York University Grossman School of Medicine, New York, NY 10016, USA;2. School of Life Sciences, Peking University, Beijing 100871, China;3. Department of Psychiatry, Department of Neuroscience and Physiology, New York University Grossman School of Medicine, Center for Neural Science, New York University, New York, NY 10016, USA;4. Department of Biomedical Engineering, New York University Tandon School of Engineering, New York, NY 11201, USA;1. Department of Diabetes and Metabolic Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan;2. Department of Biology, Koch Institute, Massachusetts Institute of Technology, Cambridge, Massachusetts;3. Toranomon Hospital, Tokyo, Japan |
| |
| Abstract: | To evaluate the potential long-term efficacy of hepatitis A vaccination for prevention of hepatitis A virus(HAV) infection, anti-HAV titers in serum were measured serially. Twelve anti-HAV-negative volunteers were injected with 0.25, 0.5 or 1.0, μg of hepatitis A vaccine at time zero, 1 and 6 months, and anti-HAV titers were monitored over a 54-month interval after the first injection. In addition, another 33 volunteers were injected with 0.5, μg of hepatitis A vaccine at time zero and 2 weeks, and anti-HAV titers were measured until 18 months. All the volunteers given two or three vaccinations seroconverted to anti-HAV by 1 month after the second injection. In subjects undergoing three injections, all remained anti-HAV positive during the observation period and the geometric mean titers (GMTs) were greater than 100 mIU/ml. In subjects undergoing two injections, anti-HAV remained positive until 18 months after the first vaccination. We therefore conclude that the hepatitis A vaccine induces a sustained anti-HAV antibody titer. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
